anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 220,921-220,950
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

220,921-220,950 of 303,780

filter-aware
05
TPD stands for Targeted Protein Degradation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
06
The slide uses a dot-matrix representation to indicate therapeutic focus areas for specific drug candidates.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
07
The slide uses a Gantt-chart style layout to show the progression of various drug programs.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
08
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
09
This is a stylistic section divider slide with an abstract background.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
12
The slide uses a side-by-side comparison framework to contrast healthy volunteer data with patient data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
14
Clinical trial baseline data table.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
16
HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
18
The slide compares cytokine inhibition across three cohorts (MAD3 Healthy Subjects, Part C AD Patients, Part C HS Patients) using two different stimuli (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
20
The slide displays 12 individual bar charts (4 for AD, 8 for HS) representing gene expression changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
21
Data based on N=7 patients. Includes error bars representing standard error or confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
25
Data presented for All HS Patients (N=12) and Moderate to Severe (N=10) subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
30
The slide uses a comparison table to highlight superior efficacy metrics for the drug candidate.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
31
The footer highlights the safety profile: no serious adverse events (SAEs), no drug-related infections, and no dose interruptions or discontinuations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
33
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
34
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
35
The slide uses a complex biological pathway diagram to illustrate the mechanism of action and the problem of redundant signaling pathways.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
37
The slide outlines a standard oncology dose-escalation study design (3+3 or similar) followed by expansion cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
38
The slide presents clinical trial data for a drug candidate, comparing PK profiles across four dose levels (DL1-DL4).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide presents longitudinal pharmacodynamic (PD) data for three targets across four dose levels, comparing clinical results to preclinical expectations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit